Eris LifesciencesNSE:ERIS +0.16%91 Interest Coverage is 4.47 as of Mar. 2026, which is 80% below its 10-year median of 22.12. GuruFocus rates NSE:ERIS with a GF Score™ of 91/100 and a GF Value™ of ₹1,645.71 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 686 Drug Manufacturers companies, Eris Lifesciences ranks worse than 73.32% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Eris Lifesciences's
Operating Income
for the
three
months ended in Mar. 2026 was ₹2,041 Mil. Eris Lifesciences's Interest Expense for the
three
months ended in Mar. 2026 was ₹-456 Mil.
Eris Lifesciences's interest coverage for the quarter that ended in Mar. 2026 was 4.47.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Eris Lifesciences's Interest Coverage or its related term are showing as below:
NSE:ERIS'
s Interest Coverage Range Over the Past 10 Years
Min: 3.03 Med: 22.12 Max: 238.69
Current: 4.36
NSE:ERIS's Interest Coverage is ranked worse than 73.32% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs NSE:ERIS: 4.36
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Eris Lifesciences Interest Coverage Related Terms
Eris Lifesciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:ERIS vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (NSE:ERIS) has a Interest Coverage of 4.47 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Eris Lifesciences and its competitors. This is 80% below median its historical median of 22.12. Over the past decade, Eris Lifesciences' Interest Coverage has ranged from 3.03 to 238.69. According to the industry distribution chart, Eris Lifesciences ranks #503 out of 686 companies in the Drug Manufacturers industry, placing it in the top 73.3%.
Is Eris Lifesciences' Interest Coverage too high?
Eris Lifesciences' current Interest Coverage of 4.47 is 80% below median its 10-year median of 22.12. Over the past 10 years, this metric has ranged from a low of 3.03 to a high of 238.69. The Drug Manufacturers industry median Interest Coverage is 12.73. Eris Lifesciences' value of 4.47 is 64.9% below this industry median. Based on the distribution chart, Eris Lifesciences ranks #503 out of 686 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #503 out of 686 companies for Interest Coverage. This places Eris Lifesciences in the lower half of its industry. The industry median Interest Coverage is 12.73. Eris Lifesciences' value of 4.47 is 64.9% below this benchmark. Historically, Eris Lifesciences' own Interest Coverage has ranged from 3.03 to 238.69 over the past decade. While the company's 10-year median is 22.12 vs. the industry median of 12.73, Eris Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current Interest Coverage of 4.47 is 64.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current Interest Coverage is 4.47, which is 80% below median its own 10-year median of 22.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,645.71, compared to a current price of ₹1,448.70 — trading 12% below its estimated fair value. The current Interest Coverage is 4.47, which is 80% below median its 10-year median of 22.12 and 64.9% below the Drug Manufacturers industry median of 12.73. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current Interest Coverage is 4.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,448.70 is trading 12% below its estimated GF Value™ of ₹1,645.71.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for NSE:ERIS:
Interest Coverage: 4.47 (80% below median its 10-year median of 22.12)
GF Value™: ₹1,645.71 vs. price of ₹1,448.70 (12% below fair value)
Industry Position: 64.9% below the Drug Manufacturers median (#503 of 686)
No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for NSE:ERIS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ERIS has been successfully added to your 
